ProMIS Neurosciences today announced that its lead product candidate for Alzheimer’s disease, PMN310, showed the desired binding profile of selectively targeting amyloid beta oligomers in a preclinical study directly comparing PMN310 to other amyloid beta-directed antibodies for Alzheimer’s disease (AD).
| |
| [17-October-2017] |
| Narrated presentation of results available on ProMIS website TSX: PMN TORONTO and CAMBRIDGE, MA, Oct. 17, 2017 /PRNewswire/ - ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that its lead product candidate for Alzheimer’s disease, PMN310, showed the desired binding profile of selectively targeting amyloid beta oligomers in a preclinical study directly comparing PMN310 to other amyloid beta-directed antibodies for Alzheimer’s disease (AD). A narrated presentation of these results is available on the ProMIS Neurosciences website at: http://bit.ly/2gp8S4t Commenting on these results, ProMIS President and CEO, Elliot Goldstein, MD, stated: “We are pleased to confirm the selective binding of PMN310 to amyloid beta oligomers, a root cause of Alzheimer’s disease. Results of prior clinical studies with other amyloid beta antibody therapeutics clearly showed that antibodies targeting amyloid beta monomer have consistently been ineffective, while those targeting amyloid beta fibrils, the main component of plaque, are associated with a dose limiting toxicity of brain swelling. Taken together, results of prior clinical trials indicate the best in class target product profile is selective binding of toxic amyloid beta oligomers.” The binding profile of PMN310 was compared to that of other candidate antibody therapeutics for AD in a preclinical study using the “dot blot” technique. Results of the study showed that PMN310 selectively binds amyloid beta oligomers (AbO), with virtually no binding to the other forms of amyloid beta. By comparison, solanezumab (Eli Lilly) showed binding mainly to Ab monomers; bapineuzumab (Johnson & Johnson/Pfizer, discontinued) showed binding to all forms of Ab (monomers, fibrils, oligomers); and aducanumab (Biogen) showed preferential binding to fibrils and oligomers. Dot blotting is a method of applying (dotting) proteins, such as Ab monomers, fibrils and oligomers, directly onto a membrane or other support. Samples of the antibody to be evaluated are then applied and the binding pattern to the various forms of amyloid beta can be observed. About ProMIS Neurosciences, Inc. ProMIS Neurosciences is a Toronto Stock Exchange listed biotech company (trading symbol: PMN.TO), headquartered in Toronto, Ontario with offices in Cambridge, Massachusetts. The Company’s mission is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS. ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform--ProMIS™ and Collective Coordinates -- to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique “precision medicine” approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS. The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For further information please consult the Company’s website at: Follow us on Twitter SOURCE ProMIS Neurosciences Inc. | ||
Company Codes: Toronto:PMN |
